Not really sure what you're getting at, teratogenicity only matters if a person is pregnant and lack of teratogenicity is in no way a requirement for FDA approval.

There are many commonly used drugs with teratogenic risks that we discontinue in pregnancy or counsel the patient on, picking randomly from a list of medications that were approved in 2023: sparsentan

I'm not sure if I'm missing something but why are you thinking teratogenicity matters when the vast majority of patients are not pregnant at a given moment?